FDA approves VIZZ eye drops; 10 hours of sharp close-up sight
VIZZ -- the first aceclidine-based eye drops to improve near vision in adults with presbyopia, which affects more than 100 million adults in the US alone, has been approved by the Food and Drug Administration (FDA) and will be available within three months.
The U.S. Food and Drug Administration (FDA) has approved a groundbreaking eye drop called VIZZ, developed by LENZ Therapeutics, that can significantly improve near vision without the need for reading glasses, according to news reports.
According to LENZ, over 128 million adults in the U.S. are affected by presbyopia, making this approval a major milestone in eye care innovation.
VIZZ works by gently contracting the iris sphincter muscle, which creates a pinhole effect that increases depth of focus.
This mechanism allows users to see nearby objects more clearly without compromising their distance vision or causing a myopic shift. The drops take effect in about 30 minutes and can last up to 10 hours, offering a full day of improved near vision from a single dose.
According to results from three Phase 3 clinical trials involving more than 680 participants, VIZZ consistently helped patients read smaller print and perform close-up tasks with ease. Safety was a key focus during testing.
Across more than 30,000 treatment days, no serious adverse events were reported. VIZZ is expected to hit the market in late 2025, offering a convenient, non-invasive alternative to reading glasses for millions of people.
Follow The Times Kuwait on X, Instagram and Facebook for the latest news updates
